Beyond Treatment Volume: When Pelvic Radiotherapy May Still Matter in High-Risk Localised Prostate Cancer

Category	Detail
Condition
Key Mechanisms	Involves radiotherapy (RT), androgen deprivation therapy (ADT), and systemic intensification with androgen receptor pathway inhibitors (ARPIs). Consider adding recent studies that support these mechanisms.
Target Population
Care Setting

Elective pelvic radiotherapy (WPRT) shows heterogeneous evidence for benefit; specify studies.
Systemic intensification with ADT is a dominant driver of therapeutic gains; clarify evidence.
Careful patient selection is crucial for the effective use of WPRT; detail selection criteria.
Advanced delivery techniques like IMRT are essential to minimize toxicity; provide examples.
Randomized trials suggest WPRT should not be universally applied; specify which trials.

WPRT may improve outcomes in selected patients with substantial occult nodal risk when combined with modern techniques; clarify selection criteria.

Utilize advanced radiotherapy techniques to enhance therapeutic ratio; provide specific examples.
Focus on patient selection based on nodal involvement and systemic therapy integration; detail methods.
Evaluate the role of pelvic RT in the context of overall systemic control; expand on evaluation methods.

Clinical Scorecard: The Role of Pelvic Radiotherapy in High-Risk Localized Prostate Cancer Beyond Treatment Volume Considerations